{"id":4442,"date":"2016-09-26T08:24:27","date_gmt":"2016-09-26T12:24:27","guid":{"rendered":"https:\/\/medicarereport.org\/?p=4442"},"modified":"2016-09-26T08:24:27","modified_gmt":"2016-09-26T12:24:27","slug":"why-pharmaceutical-companies-like-mylan-charge-so-much-for-drugs","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=4442","title":{"rendered":"Why Pharmaceutical Companies Like Mylan Charge So Much for Drugs"},"content":{"rendered":"<p>(By Melissa Quinn for The Daily Signal)<\/p>\n<p>In the wake of news that pharmaceutical company Mylan quadrupled the price of its popular EpiPen anti-allergy device over a few years, lawmakers want to know why.\u00a0 <a href=\"http:\/\/dailysignal.com\/2016\/09\/23\/why-pharmaceutical-companies-like-mylan-charge-so-much-for-drugs\/?utm_source=TDS_Email&amp;utm_medium=email&amp;utm_campaign=MorningBell&amp;mkt_tok=eyJpIjoiWXpJM1pqQXdaREkwTXprMiIsInQiOiJ0b0s2bTQ1NnArTjBKcnJyYmY2VTdIMHZzQm1FOXVwc2RXbXl0T3dWNDZJN29rZkFacFBENm5oZjFidWlIRWJweVRJWDBLWFprbHBSVkEwbVZrcmVmWlBvcm5xSXIyZkJoN0I1OUdiQmM4UT0ifQ%3D%3D\" target=\"_blank\">Continue reading article here&#8230;&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/The-Daily-Signal-logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4078\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/The-Daily-Signal-logo-300x51.png\" alt=\"The Daily Signal logo\" width=\"300\" height=\"51\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/The-Daily-Signal-logo-300x51.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/The-Daily-Signal-logo.png 464w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre><strong>Notice<\/strong>: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(By Melissa Quinn for The Daily Signal) In the wake of news that pharmaceutical company Mylan quadrupled the price of<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[],"class_list":["post-4442","post","type-post","status-publish","format-standard","hentry","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/4442","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4442"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/4442\/revisions"}],"predecessor-version":[{"id":4443,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/4442\/revisions\/4443"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4442"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4442"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4442"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}